Visão geral da empresa
InflaRx N.V. operates as a clinical-stage biopharmaceutical entity dedicated to the discovery and development of inhibitors utilizing C5a technology across Germany and the United States, targeting the treatment of various autoimmune and inflammatory diseases. The company functions within the Healthcare sector, specifically the Biotechnology industry, positioning itself to address significant unmet medical needs through its proprietary inflammatory mediator research. At a scale where the market capitalization stands at $74.46M and the workforce comprises 65 employees, the organization maintains a lean operational structure typical of early-stage development firms. The annual revenue reported for the trailing twelve months is $29,331, a figure that indicates the company is currently in a pre-revenue or minimal commercialization phase relative to its market cap, suggesting significant valuation expansion based on future potential rather than current cash flow generation. This disparity between the substantial market cap and negligible revenue highlights the speculative nature of the equity, as investors are pricing in the future success of lead product candidates like vilobelimab without the backing of established sales volumes.
Saúde financeira
The financial statements for the trailing twelve months reveal a revenue of $29,331 alongside a net income of -$45,633,780 and an EBITDA of -$48,198,212, illustrating a massive gap between top-line activity and profitability. This substantial loss relative to minimal revenue exposes a cost structure dominated by high research and development expenditures and operating overheads that far exceed current sales. The free cash flow stands at -$14,833,020, indicating that the company is burning through cash reserves rapidly to fund its clinical programs and operational expenses, thereby limiting its immediate financial flexibility. When analyzing the margins, the gross margin is recorded at 0.0%, while the operating margin displays an anomalous figure of 37898.3% and the profit margin is 0.0%, figures that reflect the accounting treatment of negligible revenue against massive costs and require careful interpretation regarding cost of goods sold and operating leverage. Despite the significant net losses, the company holds $46.46M in cash against a total debt of $897,916, resulting in a debt-to-equity ratio of 2.16. The balance sheet is effectively leveraged due to the high debt-to-equity ratio, yet the liquidity position appears robust given that cash holdings are more than 50 times the debt obligation. The current ratio is 4.13, which indicates a strong ability to meet short-term liabilities with current assets, providing a buffer against immediate financial distress despite the burning cash rate. Furthermore, the return on equity is -88.6% and the return on assets is -46.0%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently in the pursuit of long-term drug development goals rather than generating immediate returns.
Avaliação de valorização
Valuation metrics for InflaRx N.V. present a complex picture due to the lack of traditional profitability measures, with the P/E ratio (TTM) listed as N/A and a forward P/E of -1.37. The absence of a trailing P/E and the negative forward P/E imply that the market is not valuing the stock based on current or near-term earnings, as the expected earnings trajectory remains deeply negative or undefined at this stage. The price-to-book ratio is 1.55, suggesting that the market is pricing the company at a premium of 55% over its net asset value, which is unusual for a cash-burning biotech firm and indicates high investor confidence in the intangible value of its pipeline. Alternative valuation multiples show a price-to-sales ratio of 2538.67 and an EV/EBITDA of -0.60, figures that suggest the stock is valued almost entirely on the hope of future commercial success rather than current operational performance or asset liquidation value. Regarding price volatility, the 52-week high is $1.94 and the 52-week low is $0.71; assuming a current price context within this range, the stock exhibits significant fluctuation relative to its recent trading history. The beta is 1.51, indicating that the stock price is expected to be 51% more volatile than the broader market, reflecting the high risk profile associated with clinical-stage biotechnology investments.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company has not yet generated sufficient scale to calculate meaningful growth rates against a prior period. Consequently, it is impossible to determine if earnings are growing faster or slower than revenue, as both metrics are effectively zero or negative in a way that precludes standard growth analysis. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that no dividends are distributed to shareholders. This absence of dividend payouts means the company retains all its earnings, if any, and reinvests its resources back into R&D and clinical trials rather than providing income to investors. The overall growth and income profile is characterized by zero current income generation and undefined historical growth rates, relying entirely on the successful advancement of its lead product candidate to transition from a cash-burning entity to a profitable commercial business.